A-A+ Accessibility Options

What do we do?

Simply put, we want to help pancreatic cancer patients, and their doctors, to find and understand accurate and reliable information about that specific patient’s cancer that could help them to decide what the most suitable type of treatment is.  Click on the accordions below to find out more about our clinical studies and our research.

PRECISION-Panc researchers have been working to understand pancreatic cancer in more detail for many years.  Each researcher has their own specialist areas of interest.
Master Protocol open accordion arrow

The Precision-Panc Master Protocol is a “portal” protocol for patients with known or suspected pancreatic cancer to be accrued through multiple centres in the UK, with the option of being subsequently enrolled into PRIMUS (Pancreatic canceR Individualised Multi-arm Umbrella Study) examining different treatment regimens and/or biomarker development.

Eligible patients will undergo tumour biopsy and blood collection prospectively for molecular profiling at a central laboratory and the results may be used to inform enrolment to PRIMUS studies.

Our primary objective is to establish a mechanism and framework to recruit and screen patients with pancreatic cancer to perform molecular profiling, evaluation of circulating biomarkers, and enable enrolment into Precision-Panc PRIMUS studies.

The Precision-Panc Master Protocol is currently open at 12 sites around the UK, with more due to open in the coming months.

  • Current Open Sites
      • Aberdeen Royal Infirmary
      • Addenbrookes Hospital, Cambridge
      • Bristol Haematology and Oncology Centre
      • The Christie NHS Foundation Trust, Manchester
      • Glasgow Royal Infirmary
      • Imperial College Healthcare NHS Trust
      • Manchester Royal Infirmary
      • Nottingham University Hospital
      • Royal Free Hospital
      • Royal Marsden NHS Foundation Trust
      • University College London Hospitals
      • Weston Park Hospital, Sheffield
  • Pancreatic canceR Individualised Multi-arm Umbrella Studies - PRIMUS 001 open accordion arrow
    PRIMUS 001 - A PRECISION PANC CLINICAL STUDY

    An adaptive phase II study of FOLFOX-A (FOLFOX and nab-paclitaxel) versus AG (nab-paclitaxel and gemcitabine) in patients with metastatic pancreatic cancer, with integrated biomarker evaluation.

    PRIMUS 001 is a multicentre, randomised, open label, two arm, phase II interventional trial with pre-clinical and translational work including in-depth molecular profiling and biomarker discovery/development.

    PRIMUS 001 is currently open at 9 sites around the UK, with more due to open in the coming months.

  • Current Open Sites
    • Aberdeen Royal Infirmary
    • Addenbrookes Hospital, Cambridge
    • Beatston West of Scotland Cancer Centre, Glasgow
    • Bristol Haematology and Oncology Centre
    • The Christie NHS Foundation Trust, Manchester
    • Nottingham University Hospital
    • Royal Marsden NHS Foundation Trust
    • University College London Hospitals
    • Weston Park Hospital, Sheffield
  • Pancreatic canceR Individualised Multi-arm Umbrella Studies - PRIMUS 002 open accordion arrow

    PRIMUS 002 - A PRECISION PANC CLINICAL STUDY An umbrella phase II study examining two neo-adjuvant regimens (FOLFOX-A and AG) in resectable and borderline resectable Pancreatic Ductal AdenoCarcinoma (PDAC), focusing on biomarker and liquid biopsy development

    PRIMUS 002 is an integrated, open label, non-randomised, phase II trial of 2 neo-adjuvant regimens (FOLFOX-A and AG) assessing efficacy and toxicity with integrated translational work.  The study is powered on testing a proposed DNA damage response deficient biomarker for responsiveness in patients treated with FOLFOX-A; patients being treated with AG are recruited concurrently.  The study has a prospective safety assessment of neo-adjuvant chemotherapy and neo-adjuvant chemotherapy followed by CRT consisting of conventional radiotherapy with concomitant capecitabine.  This safety assessment will include all patients (FOLFOX-A and AG)

    PRIMUS 002 is currently in set up and hopes to open its first site in January 2019

    Pancreatic canceR Individualised Multi-arm Umbrella Studies - PRIMUS 003 open accordion arrow

    PRIMUS 003 - A PRECISION PANC CLINICAL STUDY

    A phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.

    PRIMUS 003, also known as the Everest study, was sponsored by AstraZeneca and is now closed to recruitment.  The database has been locked and the samples are due to be sent to Glasgow for analysis in the very near future.

    Any publications arising from the PRIMUS 003 study will be added to the website.

    Pancreatic canceR Individualised Multi-arm Umbrella Studies - PRIMUS 004 open accordion arrow

    PRIMUS 004 - A PRECISION PANC CLINICAL STUDY

    A multi-arm, non-comparative signal seeking phase II umbrella trial of marker-directed novel second-line treatments in metastatic pancreatic cancer.

    PRIMUS 004 is currently under development.  AstraZeneca have agreed to supply study drug and provide an educational grant and CRUK have endorsed the study.

    We hope to open PRIMUS 004 by September 2019.

    Research Studies open accordion arrow

    We carry out a wide range of basic and translational research studies to help us generally improve our understanding of how pancreatic cancer behaves and grows.  Over the coming months and years, we will post more details of our projects so you can follow our activities and understand how we are working actively to fight pancreatic cancer. Our experienced team of clinicians, researchers, bioinformaticians and lab staff work tirelessly with one thing in mind: improving patient outcomes.